Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine and Paclitaxel in Hormone-Refractory Prostate Cancer
NCT00003622Phase 2Withdrawn
- Start
- Jan 1999
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and paclitaxel in prostate cancer (PCa). Primary endpoint: Clinical Benefit Response. Planned start Jan 1999; status: withdrawn.
02
Drugs
vinorelbinepaclitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003622.